Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempedoic Acid/Ezetimibe/High-intensity Statin on Plaque Regression in Coronary Atherosclerosis
NCT07474649Phase 3Not yet recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of bempedoic acid, ezetimibe in Coronary atherosclerosis (CAD), mixed dyslipidemia, hypercholesterolemia, sponsored by Daiichi Sankyo Co., Ltd.. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
bempedoic acidezetimibe
03
Conditions
Coronary atherosclerosis (CAD)mixed dyslipidemiahypercholesterolemia
Beyond the preview
Go deeper on NCT07474649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07474649.